NURO News and Press, NeuroMetrix Inc. From 05/19/22

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity....

NeuroMetrix, Inc. (NURO) Q1 2022 Earnings Conference Call April 26, 2022 08:00 ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - President and Chief Executive Officer Presentation Operator Good morning and welcome to the NeuroMetrix First...

NeuroMetrix press release (NASDAQ:NURO): Q1 GAAP EPS of -$0.14. Revenue of $2.3M (+6.5% Y/Y). The gross margin rate was 77.9% in Q1 2022 versus 73.3% in Q1 2021. The Company ended the quarter with cash and equivalents of $23.8M. For further details see: NeuroMetrix GAAP EPS of -$0.14, r...

WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on populati...

AAN,OTCQX:ACDVF,ADM,ALLE,ARCC,ARCH,AVY,BBIG,BPOP,BSBR,CEQP,CNC,OTCPK:CPPMF,DHI,DISCK,ECL,EDU,ENTG,GE,GLW,GM,GPK,HSBC,HUBB,IVZ,JBLU,MKL,MMM,MSCI,NSP,NTRS,NURO,NVR,NVS,NXRT,PCAR,PEP,PII,PJT,ROP,RTX,SAN,SCL,SHW,SITC,SSTK,ST,TRU,TZOO,UBS,UPS,VLO,WM For Seeking Alpha's full earnings season calenda...

WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on April ...

WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). The ...

WOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals...

WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022. The Company will host a conference call at 8:00 a.m., Easter...

NeuroMetrix Inc. ( NASDAQ: NURO ) shot up 35% after announcing that the FDA awarded it Breakthrough Device Designation for its Quell technology . This innovative technology is designed to help reduce severe to moderate chemo symptoms that persist for at least six months afte...